




















































Coronarymicrovascular reserve and outcome
in aortic stenosis: Pathophysiological
significance vs. clinical relevance
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This editorial refers to ‘Comparison of exercise testing and
cardiovascular magnetic resonance-measured myocardial
perfusion reserve for predicting outcome in asymptomatic
aortic stenosis: the PRognostic Importance of
MIcrovascular Dysfunction in Aortic Stenosis (PRIMIDAS)
study’, by A. Singh et al. doi:10.1093/eurheartj/ehx001.
Degenerative aortic stenosis (AS) is one of the most common valvu-
lar diseases in developed countries.1 AS is a progressive disease for
which the only effective treatment is surgical or transcatheter aortic
valve replacement (AVR).2,3 Patients with mild to moderate AS re-
quire no specific valve treatment, whereas AVR is indicated in pa-
tients with severe symptomatic AS. The main conundrum in the
management of AS relates to the timing of AVR in almost half of the
patients who have severe AS but do not report clinical symptoms at
the time of diagnosis.4 This uncertainty is mainly fed by the fact that
no study has so far compared prospectively the outcomes in asymp-
tomatic patients with severe AS undergoing watchful waiting and
those undergoing AVR. Analysing all the previous studies reporting
all-cause mortality in patients with asymptomatic AS who underwent
AVR and those managed conservatively pointed to significant bias
and data heterogeneity, preventing any valid conclusion.5 Delaying
AVR in severe AS until symptoms appear represents for most clin-
icians the fear that patients may present with irreversible myocardial
damage, sudden cardiac death, or a rapidly progressive disease, espe-
cially in the absence of appropriate monitoring.6 Hence, there is a
crucial need to enable a prospective detection of patients with AS
who will benefit from AVR before they become symptomatic. Based
on the pathophysiological events occurring during valvular and myo-
cardial remodelling in AS, several clinical, biological, and imaging par-
ameters are currently being considered at different levels of evidence
to help decision-making in asymptomatic severe AS.7
Coronary microvascular dysfunction is a major player both in the
mechanism of angina and in the onset of the adverse myocardial
remodelling in severe AS.8 It can be detected as a myocardial perfu-
sion defect in the absence of obstructive epicardial coronary artery
disease, and quantified using various techniques including radio-
nuclide imaging and cardiovascular magnetic resonance (CMR)
through the myocardial perfusion reserve (MPR), the ratio of myo-
cardial blood flow during maximal hyperhaemia at exercise and at
rest.9,10 The fact that clinical symptoms occur at the end of the
ischaemic cascade, later after perfusion abnormalities could be de-
tected, places a great expectation in the evaluation of MPR in AS.
In the current issue of the journal, Singh et al. investigated the po-
tential role of comprehensive CMR relative to symptom-limited ex-
ercise testing (ETT) to predict the outcome in asymptomatic AS
[PRognostic Importance of MIcrovascular Dysfunction in Aortic
Stenosis (PRIMID AS) study].11 Such an investigation is highly rele-
vant, as the occurrence of typical symptoms during exercise testing is
the sole robust class I indication for AVR in AS patients who claimed
to be asymptomatic.2,3 The way in which this observational study has
been conducted is exemplary, as this prospective, multicentre investi-
gation has placed special emphases on carefully mitigating some het-
erogeneity bias (i.e. exclusion of patients being referred for AVR
prior to the onset of spontaneous symptoms), though the combined
outcome remains a soft endpoint. The primary endpoint occurred in
47 of the 174 (27%) recruited patients over a median follow-up time
of 1 year. As expected, both low MPR and symptom-limited ETT
were significantly associated with short-term occurrence of symp-
toms, but: (i) the value of both tests in predicting the outcome was
moderate; (ii) MPR did not perform better than symptom-limited
ETT; (iii) only symptom-limited ETT was associated with the out-
come on the multivariable analysis, irrespective of the severity of AS;
and (iv) the receiver operator characteristic (ROC) curves of both
tests predicting the onset of symptoms were almost identical, show-
ing moderate accuracy (areas under ROC curves ranging between
0.56 and 0.61), with low positive predictive values and high negative
predictive values.
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This study confirms that reduced coronary flow reserve seems to
be weakly associated with the development of symptoms in AS, des-
pite being an independent predictor of exercise capacity, inversely
associated with NYHA class in patients with severe AS undergoing
AVR, and able to predict an ischaemic event (i.e. myocardial infarc-
tion) during non-cardiac surgery in AS.12,13 Indeed, the onset of
symptoms in the individual patient with AS also depends on the se-
verity of the aortic obstruction, as well as on left ventricular (LV)
function/remodelling, and the status of the peripheral circulation.
When peripheral demands exceed the cardiac output, symptoms can
occur (Figure 1). With exercise, cardiac output rises incrementally
with workload. Increased cardiac output in severe AS is largely
dependent on increased heart rate and the coronary flow reserve
(ability of the coronary circulation to increase flow to match myocar-
dial demand) that can be altered in the case of abnormal cardiac–
coronary coupling, microvascular disease, or epicardial coronary
artery stenosis.10,14 Moreover, patients with AS (i) may be unable to
augment coronary blood flow in response to increased myocardial
workload, because vasodilation may already be near maximal;
(ii) diastolic perfusion time is limited with increased heart rate; and
(iii) there is a rapid increase in LV end-diastolic pressure, which fur-
ther reduces the effective pressure gradient for perfusion.14 All this
creates an environment vulnerable to ischaemia that contributes to
limited contractile function recruitment with subendocardial myocar-
dial dysfunction during exercise, and, as such, provides a possible
mechanism for exercise-induced symptoms (e.g. dyspnoea or angina)
and intolerance. Beyond exhausted coronary flow reserve, the ab-
sence of contractile reserve during exercise can also reflect the pres-
ence of a more advanced disease stage, with extensive myocardial
fibrosis and myocyte degeneration contributing to a mismatch be-
tween exercise afterload changes and contractility. A low flow state
with no change or even a decrease in transaortic pressure gradients
during exercise has been described in this latter condition.4,7 So, all
these complex interplays contribute to the limited accuracy of CMR
MPR and exercise ECG changes to predict clinical deterioration in
patients with asymptomatic AS, though both explore roughly the
same phenomenon, i.e. coronary flow reserve and ischaemia. The
higher number of females reaching the primary outcome in the study
of Singh et al. also highlights the gender specificities regarding the LV
remodelling process, smaller cardiac volumes and more concentric
LV geometry, different coronary flow reserve with higher resting and
hyperaemic myocardial blood flow than men, and distinctive re-
sponses to ischaemia and exercise (a more inconclusive test).4,11,14 In
practice, the present data pointed out that no single test enables
accurate stratification of asymptomatic patients with severe AS,
which calls for multiparametric strategies exploring distinct pathways
in the future. However, the use of MPR may still be considered as an
alternative to exercise testing, because of several advantages over
ETT, including notably a lower rate of inconclusive examinations, and
an objective quantification of the microvascular dysfunction as well as
LV function and remodelling.
Cardiac magnetic resonance also has the ability to characterize the
pattern and volume of myocardial fibrosis (focal vs. diffuse; subendo-
cardial vs. midwall).4 Recent studies have shown that the presence of
myocardial fibrosis in the midwall layer is more specific to pressure
overload cardiomyopathies, such as in AS, rather than to ischaemic
heart disease.4,15 Whether the localization and quantification of
myocardial fibrosis by CMR may be potentially useful to optimize risk
stratification and timing of AVR in asymptomatic patients with severe
AS is unknown. In their study, Singh et al. have also specifically ad-
dressed, for the first time, the question regarding the use of late-
gadolinium enhancement (the degree of focal fibrosis corresponding
to replacement fibrosis) and extracellular volume (diffuse fibrosis
corresponding to reactive interstitial fibrosis) measurements, both
obtainable in the same examination session as MPR.11 Although fibro-
sis is thought to play an important role in the pathophysiology of AS,
the current study showed that both measurements were not predict-
ive of the outcome in asymptomatic AS. Only a very small difference
in extracellular volume (1%) between those with and without an out-
come was observed. Actually CMR features of myocardial fibrosis
have been extensively evaluated mainly in symptomatic patients with
and without heart failure,15,16 and the findings of the present study
are nothing less than confirmation that extensive myocardial fibrosis
occurs later in the course of the disease. However, since the number
of clinical events was relatively low and a combined soft clinical end-
point was used, these data need to be confirmed in a larger cohort of
patients with severe AS.
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